Neuroleptic (Antipsychotic) Drugs: An Epidemic of Tardive Dyskinesia and Related Brain Injuries Afflicting Tens of Millions

  • Peter R. Breggin


Neuroleptic (antipsychotic) drugs affect the individual more like a viral brain disease called lethargic encephalitis than like any medical treatment. The neuroleptic pioneers saw how these drugs caused emotional indifference, disinterest, and apathy similar to lethargic encephalitis. They realized the drugs also produced neurological syndromes similar to those associated with the epidemic encephalitis, including Parkinsonism and tardive dyskinesia (TD). They predicted the new drugs could cause an epidemic of brain injury similar to the viral encephalitis. Given the severe adverse reactions TD can produce, even if the drugs brought enormous benefit, the cost would be too high. Yet the drugs have no curative value whatsoever and can only work by imposing encephalitis-like lethargy, disinterest, and apathy upon individuals, making them seemingly less troublesome to themselves and others. It is time to reconsider their use.


Tardive dyskinesia Brain injuries Neuroleptics Antipsychotics Lethargic encephalitis Tardive dystonia Tardive akathisia 


  1. Abboud, L. (2005, May 25). Treating children for bipolar disorder? Doctors try powerful drugs on kids as young as age 4 (p. D1). Wall Street Journal.Google Scholar
  2. Abilify Full Prescribing Information (the label) and Medication Guide. (2016, January). Retrieved on May 30, 2016, from Abilify homepage
  3. Abrahamson, I. (1935). Lethargic Encephalitis. New York: Privately published.Google Scholar
  4. Abrahamson, J. (2005). Overdosed America: How the pharmaceutical companies are corrupting science, misleading doctors, and threatening your health. New York: Harper Perennial.Google Scholar
  5. Addonizio, G., Susman, V. L., & Roth, S. D. (1986). Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. The American Journal of Psychiatry, 143(12), 1587–1590. doi: 10.1176/ajp.143.12.1587.PubMedCrossRefGoogle Scholar
  6. American Geriatrics Society. (2012a). Updated beers criteria for potentially inappropriate medication use in older adults by the American Geriatrics Society 2012 beers criteria update expert panel. Journal of American Geriatrics Society, 60(4), 616–631.CrossRefGoogle Scholar
  7. American Geriatrics Society. (2012b). Identifying medications that older adults should avoid or use with caution: The 2012 American Geriatrics Society Updated Beers Criteria. The American Geriatrics Society Foundation for Health in Aging. Google Scholar
  8. American Psychiatric Association. (1980). Tardive dyskinesia: Task force report. Washington, DC: Author.Google Scholar
  9. American Psychiatric Association Task Force on Tardive Dyskinesia. (1985, July). Letter to APA membership with attachment, tardive dyskinesia. Washington, DC: Author.Google Scholar
  10. American Psychiatric Association. (1992). Tardive dyskinesia: A task force report of the American psychiatric association. Washington, DC: Author.Google Scholar
  11. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, four edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.CrossRefGoogle Scholar
  12. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington, DC: American Psychiatric Association.CrossRefGoogle Scholar
  13. Angell, M. (2002). The truth about drug companies: How they deceive us and what to do about it (p. 2002). New York: Harper Random House.Google Scholar
  14. Applbaum, K. (2009). Getting to yes: Corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine and Psychiatry, 33(2), 185–215. doi: 10.1007/s11013-009-9129-3.PubMedCrossRefGoogle Scholar
  15. Asnis, G. M., Leopold, M. A., Duvoisin, R. C., & Schwartz, A. H. (1977). A survey of tardive dyskinesia in outpatients. American Journal of Psychiatry, 134, 1367–1330.PubMedCrossRefGoogle Scholar
  16. Association for Research in Nervous and Mental Disease. (1921). Acute Epidemic Encephalitis (Lethargic Encephalitis). New York: Paul B. Hoeber (Bibliolife Reproduction Series).Google Scholar
  17. Attorney General of the State of Texas. (2012, January). Texas Attorney General Secures $158 Million Agreement With Drug Maker [Johnson & Johnson for Risperdal] Over Medicaid Fraud Allegations. Retrieved on March 15, 2016, from
  18. Breggin, P. (1979). Electroshock: Its brain-disabling effects. New York: Springer.Google Scholar
  19. Breggin, P. (1981). Psychosurgery as brain-disabling therapy. In M. Dongier & E. Wittkower (Eds.), Divergent views in psychiatry (pp. 302–326). Hagerstown, Maryland: Harper & Row.Google Scholar
  20. Breggin, P. (1983). Psychiatric drugs: Hazards to the brain. New York: Springer Publishing Company.Google Scholar
  21. Breggin, P. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs. Journal of Mind and Behavior, 11, 425–463.Google Scholar
  22. Breggin, P. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesia and cognitive disorders. Brain and Cognition, 23, 8–28. doi: 10.1006/brcg.1993.1041.PubMedCrossRefGoogle Scholar
  23. Breggin, P. (1991). Toxic psychiatry. New York: St. Martin’s Press.Google Scholar
  24. Breggin, P. (1997). brain disabling treatments in psychiatry: Drugs, electroshock and the role of the FDA. New York: Springer Publishing Company.Google Scholar
  25. Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA’s Spontaneous Reporting System. Journal of Mind and Behavior, 19, 21–50.Google Scholar
  26. Breggin, P. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk and Safety and Medicine, 19, 3–15.Google Scholar
  27. Breggin, P. (2008a). Brain-disabling treatments in psychiatry, second edition: Drugs, electroshock and the psychopharmaceutical complex. New York: Springer Publishing Company.Google Scholar
  28. Breggin, P. (2008b). Medication madness: The role of psychiatric drugs in cases of violence, suicide and crime. New York: St. Martin’s Press.Google Scholar
  29. Breggin, P. (2011). Psychiatric drug-induced chronic brain impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23(4), 193–200.Google Scholar
  30. Breggin, P. (2013). Psychiatric drug withdrawal: A guide for prescriber, patients, therapists and their families. New York: Springer Pub Company.Google Scholar
  31. Breggin, P. (2014). The rights of children and parents in regard to children receiving psychiatric drugs. Children & Society, 28, 231–241.CrossRefGoogle Scholar
  32. Breggin, P. (2016). Rational principles of psychopharmacology for therapists, healthcare providers and clients. Journal of Contemporary Psychotherapy, 46(1–13), 2016.Google Scholar
  33. Breggin, P., & Stern, E. (Eds.). (1996). Psychosocial approaches to deeply disturbed persons. New York, NY: Haworth Press.Google Scholar
  34. Brill, H. (1959). Postencephalitic states or condition s. In S. Arieti (Ed.), American handbook of psychiatry (Vol. II, pp. 1163–1174). New York: Basic Books.Google Scholar
  35. Brown, P., & Funk, S. C. (1986). Tardive dyskinesia: Barriers to the professional recognition of an iatrogenic disease. Journal of Health and Social Behavior, 27, 116–132.PubMedCrossRefGoogle Scholar
  36. Brunton, L. (Ed.). (2011). Goodman and Gilman’s the pharmacological basis of therapeutics (12th ed.). New York: McGraw Hill Medical.Google Scholar
  37. Burke, R. E. (1992). Neuromuscular effects of neuroleptics: Dystonia. In J. Kane & J. Lieberman (Eds.), Adverse effects of psychotropic drugs. New York: Guilford Press.Google Scholar
  38. Burke, R. E., Fahn, S., Jankovic, J., et al. (1982). Tardive dystonia: Late onset and persistent dystonia caused by antipsychotic drugs. Neurology, 32, 1334–1346.Google Scholar
  39. Caroff, S., Hurford, I., Lybrand, J., & Campbell, C. (2011). Movement disorders induced by antipsychotic drugs: Implications of the CATIE schizophrenia trial. Neurol Clin, 29(2011), 127–148.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Chouinard, G., Annable, I., Mercier, P., & Ross-Chouinard, A. (1988). A 5-year prospective longitudinal study of tardive dyskinesia. Journal of Clinical Psychopharmacology, 8(4), 21S–26S.PubMedGoogle Scholar
  41. Cohen, D., & McCubbin, M. (1990). The political economy of tardive dyskinesia: Asymmetries in power and responsibility. Journal of Mind and Behavior, 11, 465–488.Google Scholar
  42. Cozza, S., Crawford, G., & Duncan, M. (2003). Treatment of children and adolescents, Chapter 23. InTextbook of clinical psychiatry (4th ed., pp. 1399–1145). Washington, DC: American Psychiatric Publishing.Google Scholar
  43. Davies, J. (2013). Cracked: The unhappy truth about psychiatry. New York: Pegasus.Google Scholar
  44. Decker, H. (2013). The making of DSM-III: A diagnostic manual’s conquest of American psychiatry (p. 2013). New York: Oxford University Press.Google Scholar
  45. de Girolamo, G. (1996). WHO studies in schizophrenia: An overview of the results and their implications for the understanding of the disorder. In P. Breggin & E. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 213–231). New York, NY: Haworth Press.Google Scholar
  46. Deniker, P. (1970). Introduction of neuroleptic chemotherapy into psychiatry. In F. Ayd Jr. & B. Blackwell (Eds.), Discoveries in biological psychiatry (pp. 155–164). Philadelphia: J. B. Lippincott.Google Scholar
  47. Department of Justice (DOJ) of the United States. (2013). Johnson & Johnson to pay more than $2.2 billion to resolve criminal and civil investigations: Allegations include off-label marketing and kickbacks to doctors and pharmacists, November 4, 2013. Washington, DC, U.S. Retrieved March 30, 2015, from
  48. Dorph-Petersen, K.-A., Pierri, J., Perel, J., Sun, Z., Sampson, A., & Lewis, D. (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology, 30, 1649–1661. doi: 10.1038/sj.npp.1300710.PubMedCrossRefGoogle Scholar
  49. Dwyer, D., Lu, X.-H., & Bradley, J. (2003). Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Research, 971, 31–39.PubMedCrossRefGoogle Scholar
  50. Food and Drug Administration (FDA). (2016, May 3). Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug safety communication—FDA warns about new impulse-control problems. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Retrieved May 31, 2016, from
  51. Fusar-Polia, P., Smieskovab, R., Kemptona, M., Hoc, B., Andreasen, N., & Borgwardt, S. (2013). Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience & Biobehavioral Reviews 37, 1680-1681. Retrieved May 29, 2016, from
  52. Ganzini, L., Casey, D., Hoffman, W., & McCall, A. (1993). The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Archives of Internal Medicine, 153, 1469–1475.PubMedCrossRefGoogle Scholar
  53. Glenmullen, J. (2000). Prozac Backlash. New York: Simon and Schuster.Google Scholar
  54. Goldberg, E. (1985). Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia. Schizophrenia Bulletin, 11, 255–263.PubMedCrossRefGoogle Scholar
  55. Gøtzsche, P. C. (2016). Deadly psychiatry and organized denial. Copenhagen, Denmark: People’s Press.Google Scholar
  56. Greenberg, D. (2007). Neurogenesis and stroke. CNS & Neurological Disorders—Drug Targets, 6, 321–325.CrossRefGoogle Scholar
  57. Gualtieri, C., & Barnhill, L. (1988). Tardive dyskinesia in special populations. In M. E. Wolf & A. D. Mosnaim (Eds.), Tardive dyskinesia: Biological mechanisms and clinical aspects (pp. 137–154). Washington, DC: American Psychiatric Press.Google Scholar
  58. Haag, H., Ruther, E., & Hippius, H. (1992). Tardive dyskinesia. Seattle: Hogrefe & Huber.Google Scholar
  59. Harrow, M., & Jobe, T. H. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multifollow-up study. Journal of Nervous and Mental Diseases, 195(5), 406–414.Google Scholar
  60. Herskowitz, J. (1987). Developmental neurotoxicity. In C. Popper (Ed.), Psychiatric pharmacosciences of children and adolescents (pp. 81–123). Washington, DC: American Psychiatric Press.Google Scholar
  61. Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Archives of General Psychiatry, 68(2), 128–137.PubMedPubMedCentralCrossRefGoogle Scholar
  62. IMS Institute for Health Care Informatics. (2012). The use of medicines in the United States: Review of 2011. Retrieved May 28, 2016, from
  63. International Center for the Study of Psychiatry and Psychology (ICSPP).(2009). The conscience of psychiatry: The reform work of Peter R. Breggin, MD. Ithaca, NY: Lake Edge Press.Google Scholar
  64. Inuwa, I., Horobin, R., & Williams, A. (1994). A TEM study of white blood cells from patients under neuroleptic therapy. ICEM 13 Paris [International Congress of Electron Microscopy], pp. 1091–1092.Google Scholar
  65. Jeste, D. V., Wisniewski, A. A., & Wyatt, R. J. (1986). Neuroleptic-associated tardive syndromes. Psychiatric Clinics of North America, 9, 183–192.PubMedGoogle Scholar
  66. Jeste, D. V., Lacro, J. P., Gilbert, P. L., Kline, J., & Kline, N. (1993). Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin, 19, 817–830.PubMedCrossRefGoogle Scholar
  67. Kapur, S., Zipursky, R., & Remington, G. (1999). Clinical and theoretical implications of 5-HT 2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry, 156, 286–293.PubMedGoogle Scholar
  68. Karon, B. (2005). Recurrent psychotic depression is treatable by psychoanalytic therapy without medication. Ethical Human Psychology and Psychiatry, 7, 45–56.Google Scholar
  69. Karon, B. (2003). The tragedy of schizophrenia without psychotherapy. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 331, 89–118.CrossRefGoogle Scholar
  70. Karon, B. (1989). Psychotherapy versus medications for schizophrenia: Empirical comparisons. Chapter 4. In S. Fisher & R. Greenberg (Eds.), The limits of biological treatments for psychological distress (pp. 105–150). Hillsdale, New Jersey: Lawrence Erlbaum Associates.Google Scholar
  71. Kim, H., Yumkham, S., Choi, J., Kim, E.-K., Kim, Y., Ryu, S., & Suh, P.-G. (2006). Haloperidol induces calcium ion influx via L-type calcium channels in hippocampal HN33 cells and renders the neurons more susceptible to oxidative stress. Molecules and Cells, 22, 51–57.PubMedGoogle Scholar
  72. Kirk, S., & Kutchins, H. (2003). Making us crazy. New York: Free Press.Google Scholar
  73. Kirsh, I. (2009). The emperor’s new drugs: Exploding the antidepressant myth. New York: Random House.Google Scholar
  74. Klawans, J. L. (1985). Recognition and diagnosis of tardive dyskinesia. Journal of Clinical Psychiatry, 46(4, Sec. 2), 3–7.PubMedGoogle Scholar
  75. Konopaske, G. T., Dorph-Petersen, K. A., Pierri, J. N., Wu, Q., Sampson, A. R., & Lewis, D. A. (2007). Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology, 32(6), 1216–1223. doi: 10.1038/sj.npp.1301233.PubMedCrossRefGoogle Scholar
  76. Konopaske, G. T., Dorph-Petersen, K. A., Sweet, R. A., Pierri, J. N., Zhang, W., Sampson, A. R., et al. (2008). Effect of chronic psychotic exposure to astrocyte and oligodendrocytic numbers in macaque monkeys. Biological Psychiatry, 63(8), 759–765. doi: 10.1016/j.biopsych.2007.08.018.PubMedCrossRefGoogle Scholar
  77. Leisman, G., Braun-Benjamin, O., & Melillo, R. (2014). Cognitive-motor interactions of the basal ganglia in development. Frontiers in Systems Neuroscience, 8, 1–18.CrossRefGoogle Scholar
  78. Lieberman, J. A., & Stroup, T. S. (2011). The NIMH-CATIE schizophrenia study: What did we learn? The American Journal of Psychiatry, 168(8), 770–775. doi: 10.1176/appi.ajp.2011.11010039.PubMedCrossRefGoogle Scholar
  79. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D., & Hsiao, J. (2005). For the clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209–1223. doi: 10.1056/NEJMoa051688.PubMedCrossRefGoogle Scholar
  80. Light, D. (2010). The risks of prescription drugs. New York: Columbia University.CrossRefGoogle Scholar
  81. Matheson Commission, Third Report. (1939). Epidemic encephalitis. New York: Columbia University.Google Scholar
  82. Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., et al. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry, 193, 279–288. doi: 10.1192/bjp.bp.108.050088.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Miller, L., & Jankovic, J. (1999). Drug-induced dyskinesias: An overview. In A. Joseph & R. Young (Eds.), Movement disorders in neurology and neuropsychiatry (2nd ed., pp. 2–30). Malden, Massachusetts: Blackwell Science.Google Scholar
  84. Moncrieff, J. (2007a). The myth of the chemical cure: A critique of psychiatric drug treatment. Palgrave Macmillan: Hampshire.CrossRefGoogle Scholar
  85. Moncrieff, J. (2007b). Understanding psychotropic drug action: The contribution of the brain-disabling theory. Ethical Human Psychology and Psychiatry, 9, 170–179.CrossRefGoogle Scholar
  86. Moncrieff, J. (2013). The bitterest pills: The troubling story of antipsychotic drugs. New York: Palgrave.CrossRefGoogle Scholar
  87. Mosher, L. (1996). Soteria: A therapeutic community for psychotic persons In P. R. Breggin & E. M. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 43–58). New York, NY: Haworth Press.Google Scholar
  88. Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. B., & Olfson, M. (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry, 64(9), 1032–1039.PubMedCrossRefGoogle Scholar
  89. Myslobodsky, M. (1993, September). Central determinants of attention and mood disorder in tardive dyskinesia (“tardive dysmentia”). Brain and Cognition, 23(1), 88–101.PubMedCrossRefGoogle Scholar
  90. Myslobodsky, M. (1986). Anosognosia in tardive dyskinesia: “Tardive dysmentia” or “tardive dementia”? Schizophrenia Bulletin, 12, 1–6.PubMedCrossRefGoogle Scholar
  91. Myslobodsky, M., Tomer, R., Holden, T., Kempler, S., & Sigol, M. (1985). Cognitive impairment in patients with tardive dyskinesia. Journal of Nervous and Mental Disease, 173, 156–160.PubMedCrossRefGoogle Scholar
  92. Navari, S., & Dazzan, P. (2009). Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine, 39(11), 1763–1777. doi: 10.1017/S0033291709005315.PubMedCrossRefGoogle Scholar
  93. Pachter, W., Fox, R., Zimbardo, P., & Antonuccio, D. (2007). Corporate funding and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015. doi: 10.1037/0003-066X.62.9.1005.PubMedCrossRefGoogle Scholar
  94. Ramaekers, J. (1998). Behavioural toxicity of medicinal drugs practical consequences, incidence, management and avoidance. Drug Safety, 18(3), 189–208.PubMedCrossRefGoogle Scholar
  95. Richardson, M. A., Craig, T., & Branchey, M. (1982). Intra-patient variability in the measurement of tardive dyskinesia. Psychopharmacology, 76, 269–272.PubMedCrossRefGoogle Scholar
  96. Risperdal. (2014, April). FDA-approved Full Prescribing Information (the label). Retrieved Janssen homepage May 30, 2016, from
  97. Rosebush, P., & Mazurek, M. F. (1999). Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology, 52(4), 782–785.PubMedCrossRefGoogle Scholar
  98. Sachdev, P. (1993). Clinical characteristics of 15 patients with tardive dystonia. American Journal of Psychiatry, 150, 498–500. doi: 10.1176/ajp.150.3.498.PubMedCrossRefGoogle Scholar
  99. Saltz, G. L., Woerner, M. G., Kane, J. M., Lieberman, J. A., Alvir, J. M. J., Bergmann, K. J., et al. (1991). Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association, 266, 2402–2406.PubMedCrossRefGoogle Scholar
  100. Sarchet, P. (2011). Harvard scientists disciplined for not declaring ties to drug companies. Retrieved from
  101. Schatzberg, A., Cole, J., & DeBattista, C. (1997). Manual of clinical psychopharmacology (3rd ed.). Washington, DC: American Psychiatric Association.Google Scholar
  102. Seikkula, J. (2006). Five year experience of first-episode nonaffective psychosis in open-dialogue approach. Journal of Psychotherapy Research, 16, 214–228.CrossRefGoogle Scholar
  103. Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up of first episode schizophrenia. Ethical Human Sciences and Services, 5(3), 163–182.Google Scholar
  104. Smith, J., Kucharski, M., Oswald, T., & Waterman, M. (1979). A systematic investigation of tardive dyskinesia inpatients. American Journal of Psychiatry, 136, 918–922. doi: 10.1176/ajp.136.7.918.PubMedCrossRefGoogle Scholar
  105. Smith, K., & Laboratories, F. (1964). Ten years experience with thorazine: 1954–1964. Philadelphia: Author.Google Scholar
  106. Southerland, M. R. (2005, June 9). Addendum to previous review: Further analysis of tardive dyskinesia cases [involving metoclopramide], (NDA 21-645), (DO5036). Rockville, Maryland: Safety Evaluator, Division of Drug Risk Evaluation, Food and Drug Administration.Google Scholar
  107. Teller, D., & Denber, H. (1970). Mescaline and phenothiazines: Recent studies on subcellular localization and effects upon membranes. In A. Lajtha (Ed.), Protein metabolism of the nervous system (pp. 685–698). New York: Plenum.CrossRefGoogle Scholar
  108. Van Haren, N., Schnack, H., Cahn, W., Heuvel, P., Lepage, C., Collins, L., et al. (2011). Changes in cortical thickness during the course of illness in schizophrenia. Archives of General Psychiatry, 68(9), 871–880. doi: 10.1001/archgenpsychiatry.2011.88.PubMedCrossRefGoogle Scholar
  109. Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67–72.PubMedCrossRefGoogle Scholar
  110. Van Putten, T. (1975). The many faces of akathisia. Comprehensive Psychiatry, 16, 43–46.PubMedCrossRefGoogle Scholar
  111. Van Putten, T., May, P., & Marder, S. (1984). Akathisia with haloperidol and thiothixene. Psychopharmacology Bulletin, 20, 114–117.PubMedGoogle Scholar
  112. Van Putten, T., & May, P. (1978). Akinetic depression in schizophrenia. Archives of General Psychiatry, 35, 1101–1107.PubMedCrossRefGoogle Scholar
  113. Von Economo, C. (1931). Encephalitis lethargica: Its sequelae and treatment. London: Oxford University Press.Google Scholar
  114. Watters, E. (2011). Crazy like us: The globalization of the American psyche. New York: Free Press.Google Scholar
  115. Whitaker, R. (2010). Anatomy of an epidemic. New York: Crown.Google Scholar
  116. Whitaker, R., & Cosgrove, L. (2015). Psychiatry under the influence: Institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan.CrossRefGoogle Scholar
  117. Wojcieszek, J. (1998). Drug-induced movement disorders. Chapter 12. In J. Biller (Ed.), Iatrogenic neurology (pp. 215–231). Boston: Butterworth-Heinemann.Google Scholar
  118. Wolf, M. E., & Brown, P. (1987). Overcoming institutional and community resistance to a tardive dyskinesia management program. Hospital and Community Psychiatry, 38, 65–68.PubMedGoogle Scholar
  119. Woods, S., Morgenstern, H., Saksa, J., Walsh, B., Sullivan, M., Money, R., et al. (2010). Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. Journal of Clinical Psychiatry, 71, 463–474. doi: 10.4088/JCP.07m03890yel.PubMedPubMedCentralCrossRefGoogle Scholar
  120. Worster-Drought, C., & Hardcastle, D. N. (1924–1925). A contribution to the psychopathology of residual encephalitis lethargica. Journal of Neurology and Psychopathology., 5, 146–150.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Yassa, R., Nastase, C., Camille, Y., & Belzile, L. (1988). Tardive dyskinesia in a psychogeriatric population. In M. E. Wolf & A. D. Mosnaim (Eds.), Tardive dyskinesia: Biological mechanisms and clinical aspects. Washington, DC: American Psychiatric Press.Google Scholar
  122. Yassa, R., Nastase, C., Dupont, D., & Thibeau, M. (1992). Tardive dyskinesia in elderly psychiatric patients: A 5-year study. American Journal of Psychiatry, 149, 1206–1211. doi: 10.1176/ajp.149.9.1206.PubMedCrossRefGoogle Scholar
  123. Yu, X. (2011, July 2). Three professors face sanctions following Harvard Medical School inquiry. The Harvard Crimson, p. 1.Google Scholar
  124. Zarrouf, F., & Bhanot, V. (2007). Neuroleptic malignant syndrome: Don’t let your guard down yet. Current Psychiatry, 6(8), 89–95.Google Scholar
  125. Zutshi, D., Cloud, L., Factor. S. (2014). Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y), 4, 266. Published online October 23, 2014. doi:  10.7916/D8MS3R8C. Retrieved May 29, 2016, from

Copyright information

© The Author(s) 2017

Authors and Affiliations

  • Peter R. Breggin
    • 1
  1. 1.Private PracticeIthacaUSA

Personalised recommendations